Heart-Rate-Corrected QT Interval Response to Ramosetron during Robot-Assisted Laparoscopic Prostatectomy: A Randomized Trial
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Randomization and Interventions
2.3. Anesthesia
2.4. Data Collection and Outcome Assessments
2.5. Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Gan, T.J.; Belani, K.G.; Bergese, S.; Chung, F.; Diemunsch, P.; Habib, A.S.; Jin, Z.; Kovac, A.L.; Meyer, T.A.; Urman, R.D.; et al. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesth. Analg. 2020, 131, 411–448. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.H.; Seo, J.H.; Min, K.T.; Lim, Y.J.; Jeong, S.W.; Lee, E.K.; Choi, B.M.; Noh, G.J. Population Pharmacokinetics and Prophylactic Anti-Emetic Efficacy of Ramosetron in Surgical Patients. Br. J. Clin. Pharmacol. 2016, 82, 762–772. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ayad, R.F.; Assar, M.D.; Simpson, L.; Garner, J.B.; Schussler, J.M. Causes and Management of Drug-Induced Long qt Syndrome. Proc. Bayl. Univ. Med. Cent. 2010, 23, 250–255. [Google Scholar] [CrossRef] [PubMed]
- Kim, T.K.; Cho, Y.J.; Lim, C.W.; Min, J.J.; Choi, E.K.; Hong, D.M.; Jeon, Y. Effect of Ramosetron on Qtc Interval: A Randomised Controlled Trial in Patients Undergoing Off-Pump Coronary Artery Bypass Surgery. BMC Anesthesiol. 2016, 16, 56. [Google Scholar] [CrossRef] [Green Version]
- Niemeijer, M.N.; van den Berg, M.E.; Eijgelsheim, M.; Rijnbeek, P.R.; Stricker, B.H. Pharmacogenetics of Drug-Induced qt Interval Prolongation: An Update. Drug Saf. 2015, 38, 855–867. [Google Scholar] [CrossRef] [Green Version]
- Staikou, C.; Stamelos, M.; Stavroulakis, E. Impact of Anaesthetic Drugs and Adjuvants on Ecg Markers of Torsadogenicity. Br. J. Anaesth. 2014, 112, 217–230. [Google Scholar] [CrossRef] [Green Version]
- Cao, L.; Yang, Z.; Qi, L.; Chen, M. Robot-Assisted and Laparoscopic vs Open Radical Prostatectomy in Clinically Localized Prostate Cancer: Perioperative, Functional, and Oncological Outcomes: A Systematic Review and Meta-Analysis. Medicine 2019, 98, e15770. [Google Scholar] [CrossRef]
- Lee, S.H.; Seo, H.J.; Lee, N.R.; Son, S.K.; Kim, D.K.; Rha, K.H. Robot-Assisted Radical Prostatectomy Has Lower Biochemical Recurrence Than Laparoscopic Radical Prostatectomy: Systematic Review and Meta-Analysis. Investig. Clin. Urol. 2017, 58, 152–163. [Google Scholar] [CrossRef] [Green Version]
- Kadono, Y.; Yaegashi, H.; Machioka, K.; Ueno, S.; Miwa, S.; Maeda, Y.; Miyagi, T.; Mizokami, A.; Fujii, Y.; Tsubokawa, T.; et al. Cardiovascular and Respiratory Effects of the Degree of Head-Down Angle During Robot-Assisted Laparoscopic Radical Prostatectomy. Int. J. Med. Robot. 2013, 9, 17–22. [Google Scholar] [CrossRef]
- Kim, N.Y.; Han, D.W.; Koh, J.C.; Rha, K.H.; Hong, J.H.; Park, J.M.; Kim, S.Y. Effect of Dexmedetomidine on Heart Rate-Corrected qt and Tpeak-Tend Intervals During Robot-Assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position: A Prospective, Randomized, Double-Blinded, Controlled Study. Medicine 2016, 95, e3645. [Google Scholar] [CrossRef]
- Kim, S.H.; Lee, S.M.; Kim, Y.K.; Park, S.Y.; Lee, J.H.; Cho, S.H.; Chai, W.S.; Jin, H.C. Effects of Prophylactic Ramosetron and Ondansetron on Corrected qt Interval During General Anesthesia. J. Clin. Anesth. 2014, 26, 511–516. [Google Scholar] [CrossRef] [PubMed]
- Vandenberk, B.; Vandael, E.; Robyns, T.; Vandenberghe, J.; Garweg, C.; Foulon, V.; Ector, J.; Willems, R. Qt Correction across the Heart Rate Spectrum, in Atrial Fibrillation and Ventricular Conduction Defects. Pacing Clin. Electrophysiol. 2018, 41, 1101–1108. [Google Scholar] [CrossRef] [PubMed]
- Straus, S.M.; Kors, J.A.; De Bruin, M.L.; van der Hooft, C.S.; Hofman, A.; Heeringa, J.; Deckers, J.W.; Kingma, J.H.; Sturkenboom, M.C.; Stricker, B.H.; et al. Prolonged Qtc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults. J. Am. Coll. Cardiol. 2006, 47, 362–367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Isbister, G.K.; Page, C.B. Drug Induced qt Prolongation: The Measurement and Assessment of the qt Interval in Clinical Practice. Br. J. Clin. Pharmacol. 2013, 76, 48–57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roden, D.M. Drug-Induced Prolongation of the qt Interval. N. Engl. J. Med. 2004, 350, 1013–1022. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kuryshev, Y.A.; Brown, A.M.; Wang, L.; Benedict, C.R.; Rampe, D. Interactions of the 5-Hydroxytryptamine 3 Antagonist Class of Antiemetic Drugs With Human Cardiac Ion Channels. J. Pharmacol. Exp. Ther. 2000, 295, 614–620. [Google Scholar]
- Li, K.; Vo, K.; Lee, B.K.; Addo, N.; Coralic, Z. Effect of a Single Dose of i.V. Ondansetron on Qtc Interval in Emergency Department Patients. Am. J. Health. Syst Pharm. 2018, 75, 276–282. [Google Scholar] [CrossRef] [Green Version]
- Hafermann, M.J.; Namdar, R.; Seibold, G.E.; Page, R.L., 2nd. Effect of Intravenous Ondansetron on qt Interval Prolongation in Patients with Cardiovascular Disease and Additional Risk Factors for Torsades: A Prospective, Observational Study. Drug Healthc. Patient Saf. 2011, 3, 53–58. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.H.; Yoo, E.K.; Song, I.K.; Kim, J.T.; Kim, H.S. Effect of Ramosetron on the qt Interval During Sevoflurane Anaesthesia in Children: A Prospective Observational Study. Eur. J. Anaesthesiol. 2015, 32, 330–335. [Google Scholar] [CrossRef]
- Panikkath, R.; Reinier, K.; Uy-Evanado, A.; Teodorescu, C.; Hattenhauer, J.; Mariani, R.; Gunson, K.; Jui, J.; Chugh, S.S. Prolonged Tpeak-to-Tend Interval on the Resting Ecg Is Associated With Increased Risk of Sudden Cardiac Death. Circ. Arrhythm. Electrophysiol. 2011, 4, 441–447. [Google Scholar] [CrossRef] [Green Version]
- Basiri, A.; de la Rosette, J.J.; Tabatabaei, S.; Woo, H.H.; Laguna, M.P.; Shemshaki, H. Comparison of Retropubic, Laparoscopic and Robotic Radical Prostatectomy: Who Is the Winner? World J. Urol. 2018, 36, 609–621. [Google Scholar] [CrossRef] [PubMed]
- Lestar, M.; Gunnarsson, L.; Lagerstrand, L.; Wiklund, P.; Odeberg-Wernerman, S. Hemodynamic Perturbations During Robot-Assisted Laparoscopic Radical Prostatectomy in 45° Trendelenburg Position. Anesth. Analg. 2011, 113, 1069–1075. [Google Scholar] [CrossRef] [PubMed]
- Stone, J.; Dyke, L.; Fritz, P.; Reigle, M.; Verrill, H.; Bhakta, K.; Boike, G.; Graham, J.; Gerbasi, F. Hemodynamic and Hormonal Changes During Pneumoperitoneum and Trendelenburg Positioning for Operative Gynecologic Laparoscopy Surgery. Prim. Care Update Ob. Gyns. 1998, 5, 155. [Google Scholar] [CrossRef]
- Schwartz, P.J. Cardiac Sympathetic Denervation to Prevent Life-Threatening Arrhythmias. Nat. Rev. Cardiol. 2014, 11, 346–353. [Google Scholar] [CrossRef]
- Muchatuta, N.A.; Paech, M.J. Management of Postoperative Nausea and Vomiting: Focus on Palonosetron. Ther. Clin. Risk Manag. 2009, 5, 21–34. [Google Scholar]
Control Group (N = 28) | Ramosetron Group (N = 26) | p-Value | |
---|---|---|---|
Age (years) | 65.8 ± 6.5 | 68.0 ± 7.0 | 0.234 |
Height (cm) | 168.0 ± 6.8 | 167.1 ± 6.5 | 0.628 |
Weight (kg) | 71.1 ± 9.4 | 67.9 ± 9.8 | 0.222 |
ASA class (I/II) | 8/20 | 11/15 | 0.441 |
Hypertension | 15 (54) | 11 (42) | 0.579 |
Diabetes mellitus | 6 (21) | 3 (12) | 0.543 |
COPD | 0 (0) | 2 (8) | 0.439 |
Postoperative hospital day | 2 (2–3) | 3 (2–4) | 0.115 |
Anesthesia duration (min) | 160 (145–178) | 160 (135–205) | 0.768 |
Operation duration (min) | 108 (95–127) | 121 (103–148) | 0.258 |
Fluid intake (mL) | 1565 ± 356 | 1457 ± 557 | 0.463 |
Blood loss (mL) | 200 (100–300) | 225 (100–400) | 0.732 |
Urine output (mL) | 150 (100–240) | 200 (100–200) | 0.895 |
Control Group (N = 28) | Ramosetron Group (N = 26) | p-Value | |
---|---|---|---|
QTcB interval > 450 ms | 8 (29) | 12 (46) | 0.291 |
QTcB interval > 500 ms | 1 (4) | 2(8) | 0.947 |
QTcF interval > 450 ms | 9 (32) | 9 (35) | >0.999 |
QTcF interval > 500 ms | 1 (4) | 1 (4) | >0.999 |
∆ QTcB interval (ms) | 40.3 (26.5–62.9) | 49.9 (32.4–68.4) | 0.232 |
>20 ms | 24 (86) | 24 (92) | 0.736 |
>40 ms | 14 (50) | 19 (73) | 0.145 |
>60 ms | 9 (32) | 8 (31) | >0.999 |
>80 ms | 2 (7) | 2 (8) | 0.736 |
∆ QTcF interval (ms) | 42.0 (31.2–65.5) | 49.8 (41.7–61.4) | 0.253 |
>20 ms | 26 (93) | 24 (92) | >0.999 |
>40 ms | 15 (54) | 22 (85) | 0.020 |
>60 ms | 9 (32) | 7 (27) | 0.903 |
>80 ms | 1 (4) | 3 (12) | 0.551 |
Control Group (N = 28) | Ramosetron Group (N = 26) | p-Value | |
---|---|---|---|
Mean arterial pressure (mmHg) | Pgroup×time = 0.376 | ||
Before induction | 98.21 ± 11.98 | 95.50 ± 8.40 | 0.3863 |
After induction | 74.57 ± 9.20 * | 78.88 ± 15.53 * | 0.169 |
T-5 min | 90.82 ± 12.90 * | 94.42 ± 14.69 | 0.2506 |
T-30 min | 80.59 ± 9.28 * | 82.46 ± 10.97 * | 0.4887 |
T-60 min | 77.60 ± 11.83 * | 81.71 ± 9.98 * | 0.4667 |
T-off | 71.43 ± 9.14 * | 72.77 ± 11.96 * | 0.6686 |
End of surgery | 72.43 ± 8.57 * | 77.08 ± 13.06 * | 0.1384 |
Heart rate (beats/min) | Pgroup×time = 0.5246 | ||
Before induction | 69.78 ± 10.83 | 71.15 ± 11.78 | 0.6069 |
After induction | 68.04 ± 9.72 | 71.9 ± 11.22 | 0.1474 |
T-5 min | 67.47 ± 8.85 | 66.97 ± 8.45 | 0.6661 |
T-30 min | 65.86 ± 8.59 | 68.29 ± 9.70 | 0.3689 |
T-60 min | 64.42 ± 9.38 | 66.61 ± 8.20 | 0.7098 |
T-off | 64.64 ± 8.62 * | 68.13 ± 10.15 | 0.1986 |
End of surgery | 66.24 ± 11.06 | 67.19 ± 7.76 | 0.5649 |
EtCO2 (mmH2O) | Pgroup×time = 0.0666 | ||
After induction | 35.61 ± 2.48 | 35.04 ± 2.66 | 0.725 |
T-5 min | 42.93 ± 6.43 | 43.88 ± 7.77 | 0.5544 |
T-30 min | 41.29 ± 6.10 | 43.88 ± 7.19 | 0.1088 |
T-60 min | 41.12 ± 6.23 | 43.18 ± 6.62 | 0.2027 |
T-off | 43.86 ± 5.90 | 47.12 ± 7.01 | 0.0538 |
End of surgery | 40.11 ± 5.95 | 39.54 ± 4.72 | 0.725 |
EtSevo (%) | Pgroup×time = 0.6969 | ||
After induction | 1.40 ± 0.24 | 1.35 ± 0.21 | 0.3609 |
T-5 min | 1.73 ± 0.20 | 1.62 ± 0.27 | 0.0546 |
T-30 min | 1.75 ± 0.18 | 1.63 ± 0.19 | 0.0255 |
T-60 min | 1.74 ± 0.21 | 1.62 ± 0.19 | 0.0297 |
T-off | 1.67 ± 0.17 | 1.57 ± 0.18 | 0.084 |
End of surgery | 1.54 ± 0.16 | 1.40 ± 0.18 | 0.0093 |
Control Group (N = 28) | Ramosetron Group (N = 26) | p Value | |
---|---|---|---|
Tp-e interval (ms) | Pgroup×time = 0.7503 | ||
Before induction | 64.13 ± 20.86 | 69.74 ± 12.28 | 0.2394 |
After induction | 58.59 ± 13.04 | 63.12 ± 9.22 | 0.3414 |
T-5 min | 60.17 ± 19.92 | 63.82 ± 10.88 | 0.4555 |
T-30 min | 61.30 ± 23.00 | 64.25 ± 11.72 | 0.8705 |
T-60 min | 55.46 ± 12.69 | 63.18 ± 11.86 | 0.476 |
T-off | 64.76 ± 30.25 | 64.45 ± 9.82 | 0.9393 |
End of surgery | 61.27 ± 22.13 | 62.68 ± 9.66 | 0.7618 |
Tp-e/QT ratio | Pgroup×time = 0.533 | ||
Before induction | 0.18 ± 0.04 | 0.19 ± 0.03 | 0.1317 |
After induction | 0.16 ± 0.03 * | 0.17 ± 0.03 * | 0.2041 |
T-5 min | 0.16 ± 0.04 * | 0.16 ± 0.03 * | 0.5549 |
T-30 min | 0.16 ± 0.04 * | 0.16 ± 0.02 * | 0.9513 |
T-60 min | 0.14 ± 0.02 * | 0.15 ± 0.02 * | 0.6552 |
T-off | 0.16 ± 0.05 * | 0.16 ± 0.02 * | 0.9883 |
End of surgery | 0.15 ± 0.05 * | 0.15 ± 0.02 * | 0.8215 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, B.; Kim, S.Y.; Kim, S.H.; Yang, H.; Jin, J.H.; Choi, S.H. Heart-Rate-Corrected QT Interval Response to Ramosetron during Robot-Assisted Laparoscopic Prostatectomy: A Randomized Trial. J. Pers. Med. 2022, 12, 811. https://doi.org/10.3390/jpm12050811
Lee B, Kim SY, Kim SH, Yang H, Jin JH, Choi SH. Heart-Rate-Corrected QT Interval Response to Ramosetron during Robot-Assisted Laparoscopic Prostatectomy: A Randomized Trial. Journal of Personalized Medicine. 2022; 12(5):811. https://doi.org/10.3390/jpm12050811
Chicago/Turabian StyleLee, Bora, So Yeon Kim, Seung Hyun Kim, Hyukjin Yang, Jeong Hyun Jin, and Seung Ho Choi. 2022. "Heart-Rate-Corrected QT Interval Response to Ramosetron during Robot-Assisted Laparoscopic Prostatectomy: A Randomized Trial" Journal of Personalized Medicine 12, no. 5: 811. https://doi.org/10.3390/jpm12050811